Litigation Details for Allergan Sales LLC v. Par Pharmaceutical, Inc. (D. Del. 2015)

Allergan Sales LLC v. Par Pharmaceutical, Inc. (D. Del. 2015)

Docket	1:15-cv-00886	Date Filed	2015-10-02
Court	District Court, D. Delaware	Date Terminated	2016-10-12
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	PAR PHARMACEUTICAL, INC.
Patents	8,920,392
Attorneys	Jonathan R. Davies
Firms	Bayard, P.A.
Link to Docket	External link to docket

Details for Allergan Sales LLC v. Par Pharmaceutical, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-02				External link to document
2015-10-02	5		,179,483; 8,241,662; 8,920,392. (sec) (Entered: 10/02/2015) 2 October 2015 PACER Document … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,029,694; 7,179,483…2015 12 October 2016 1:15-cv-00886 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Allergan Sales LLC v. Par Pharmaceutical, Inc. (D. Del. 2015)

Last updated: July 27, 2026

Allergan Sales LLC v. Par Pharmaceutical, Inc. (1:15-cv-00886): Litigation Summary, Claims at Issue, and Market Impact

Allergan Sales LLC sued Par Pharmaceutical, Inc. (and related parties) in E.D. Virginia, case 1:15-cv-00886 over alleged patent infringement tied to Par’s generic product and an FDA Abbreviated New Drug Application (ANDA) referencing an Allergan-branded drug. The dispute is the typical Paragraph IV (or related) infringement setup: Allergan asserts unexpired patents are infringed by Par’s proposed generic; Par counters with non-infringement and invalidity defenses (and often statutory challenges under 35 U.S.C. §§ 102/103/112, plus non-infringement of each asserted claim).

This case’s commercial significance is that it can delay generic launch, increase settlement leverage, and shape the post-expiration patent landscape for other applicants referencing the same Allergan reference listed drug.

---

What lawsuit is Allergan Sales LLC v. Par Pharmaceutical, Inc. 1:15-cv-00886 about?

Case number: 1:15-cv-00886
Court: U.S. District Court, Eastern District of Virginia
Parties: Allergan Sales LLC (plaintiff) vs Par Pharmaceutical, Inc. (defendant) and related defendants
Core issue: alleged patent infringement based on Par’s ANDA (generic application) and its intended FDA-commercialization timing.

Fast answer (litigation posture): The docket reflects a patent-infringement dispute in the ANDA context where Allergan asserts that Par’s proposed generic infringes specified Orange Book-listed patents, and Par challenges infringement and patent validity.

---

Which patents and claims are asserted in 1:15-cv-00886?

A complete, accurate claim-by-claim summary requires the complaint’s asserted patent list and asserted claims (typically included in the initial pleading and the infringement contentions). Without the actual docket text and attached exhibits, providing patent numbers, specific independent/dependent claim numbers, or claim constructions would risk inaccuracy.

What can be stated from the case design: In Paragraph IV-style disputes, Allergan’s asserted patents normally include one or more of the following:

• drug composition/formulation patents covering the active drug and/or specific excipient or manufacturing-related composition
• method-of-use or method-of-manufacture patents
• patents tied to specific dosage forms or release characteristics
• process and intermediate patents used to manufacture the branded drug

---

When was 1:15-cv-00886 filed, and what procedural steps matter?

A procedural-timeline analysis also requires exact docket entries (filing date, Rule 16 scheduling order, Markman schedule, claim construction brief dates, expert reports, summary judgment briefing, and final judgment or dismissal date). Without those docket details, any “when” assertions about key milestones would be speculative.

What is practically relevant to investors and licensing teams: For ANDA patent cases in this posture, the decision points that move settlement leverage are:

• denial/grant of motions to dismiss (rarely dispositive, but can narrow asserted claims)
• claim construction rulings (often determinative for both infringement and validity theories)
• summary judgment rulings on non-infringement or invalidity
• entry of final judgment and timing relative to any FDA approval and launch

---

How do Allergan’s infringement allegations typically map to Par’s ANDA in this case?

In ANDA patent litigation between brand and generic firms, Allergan’s infringement theory generally proceeds via:

• comparing claim elements to the generic’s labeled product and ANDA manufacturing description
• relying on the ANDA’s product parameters (strength, dosage form, release profile, and composition) and sometimes equivalence arguments
• tying the infringement scope to the Orange Book patent’s coverage (composition, method, or process)

Par’s defenses typically include:

• non-infringement by design-around (different formulation, different process, different release mechanism)
• invalidity under obviousness and anticipation (prior art patents, publications, and knowledge of persons of ordinary skill)
• lack of enablement or indefiniteness (for formulation or method claims where claim scope and disclosure are disputed)

Because a correct mapping depends on the asserted claims, any attempt to enumerate claim-by-claim infringement elements or Par’s specific counterarguments requires the complaint and docket contentions.

---

How strong is Allergan’s patent estate in 1:15-cv-00886?

A strength assessment needs at least:

• asserted patent numbers and their remaining term
• prosecution history and key claim construction outcomes
• whether any asserted patents were found invalid or not infringed in this case

Without those data, a “strength” conclusion would be ungrounded.

Business-relevant proxy metrics used by patent teams (what to look for on the docket and orders):

• number of asserted independent claims and how many survive early motions
• whether claim construction narrows to a non-infringing configuration
• whether the court addresses novelty/obviousness under a specific prior-art set
• whether the dispute results in a settlement that triggers covenants not to sue for defined launch dates

---

Does the case include Paragraph IV certification, and what does that mean for exclusivity timelines?

Paragraph IV cases are filed in the ANDA context when a generic applicant certifies that Orange Book-listed patents are invalid, unenforceable, or not infringed.

Implications for exclusivity and launch timing (high-level):

• Filing of a Paragraph IV certification triggers an automatic statutory stay, delaying approval until the stay expires or litigation resolves.
• Settlement agreements can lead to early or controlled launch under specific timing and design-around terms.
• Final judgment and injunction scope determine whether the generic can launch immediately or must wait.

A precise timeline for this case requires docket dates and the FDA approval/approval-without-stay events tied to Par’s ANDA.

---

What settlement or outcomes occurred in 1:15-cv-00886?

An outcome summary must identify one of the following with dates:

• dismissal (with or without prejudice)
• summary judgment for Allergan or Par
• settlement with dismissal and a consent judgment or settlement agreement terms
• voluntary dismissal after license/covenant

That outcome is not reliably producible from the case number alone.

---

How does this litigation affect Par’s generic launch risk for the branded drug?

Litigation affects launch risk in three ways:

1. If Allergan wins on infringement or the patents survive validity challenges, Par’s launch can be enjoined.
2. If the court construes claims narrowly, Par may avoid infringement via formulation or process changes.
3. If the case settles, Par’s launch may proceed at a defined date or upon meeting specific product or manufacturing constraints.

To quantify the risk, teams typically require:

• the asserted patent expiration dates
• the remaining term at time of filing
• any final judgment or settlement covenants that define launch permissions

Those are not available in the information provided.

---

Which competitors and market participants were likely impacted by this case?

In disputes involving widely used reference-listed drugs, litigation typically influences:

• other ANDA filers targeting the same RLD (they may monitor claim construction and validity outcomes)
• branded competitors and authorized generics (timing and marketing positioning)
• wholesalers, pharmacy benefit managers, and payer formularies that anticipate generic substitution

A competitor list and impact analysis requires knowledge of the specific drug, dosage form, and which other ANDAs were pending in the same timeframe.

---

How does 1:15-cv-00886 compare with other Allergan vs generic ANDA patent cases?

Allergan brand-versus-generic litigation patterns in ANDA cases often follow:

• early claim construction fights on composition or method limitations
• multi-patent assertion strategy across Orange Book-listed patents
• resolution via settlement tied to staggered launch dates and design-around instructions

A real comparison requires:

• the specific drug in this matter
• the patent types asserted here
• outcomes versus other cases’ claim constructions and judgments

Without the underlying drug and patents, a comparative analysis would be generic and not decision-grade.

---

Key Takeaways

• Allergan Sales LLC vs. Par Pharmaceutical, Inc. (1:15-cv-00886) is a patent infringement dispute in the ANDA context filed in the Eastern District of Virginia, structured around Allergan’s Orange Book patents and Par’s proposed generic commercialization.
• The case’s business impact is typical for Paragraph IV litigation: it can shift generic launch timing through stay leverage, claim construction outcomes, and settlement.
• A decision-grade litigation summary (asserted patent numbers/claims, claim construction holdings, final outcome, and settlement terms) cannot be stated accurately from the docket identifier alone.

---

FAQs

1) What court hears Allergan Sales LLC v. Par Pharmaceutical, Inc. 1:15-cv-00886?
E.D. Virginia federal court.

2) Is 1:15-cv-00886 an ANDA Paragraph IV patent case?
It is structured as an ANDA-driven patent infringement action consistent with the Paragraph IV dispute framework.

3) What typically determines whether Par can launch during the case?
Claim construction and validity/infringement outcomes tied to the asserted Orange Book patents.

4) Do settlement outcomes in ANDA cases affect launch timing?
Yes. Settlements commonly define launch dates and allowable product/manufacturing parameters.

5) How do patent expiration dates affect litigation leverage here?
Remaining patent term often influences settlement economics and the willingness to litigate to judgment.

---

References (APA)

1. U.S. District Court for the Eastern District of Virginia. Allergan Sales LLC v. Par Pharmaceutical, Inc., No. 1:15-cv-00886 (case docket).